Study of Sacituzumab Govitecan in Patients With Solid Tumor

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Solid Tumor
Interventions
DRUG

Sacituzumab Govitecan-hziy

Administered intravenously

Trial Locations (13)

43006

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

100006

Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing

100021

Chinese Academy of Medical Sciences Cancer Hospital, Beijing

100142

Beijing Cancer Hospital, Beijing

130021

The First Hospital of Jilin University, Changchun

150076

Harbin Medical University Cancer Hospital, Harbin

210029

Jiangsu Province Hospital, Nanjing

230001

Anhui Provincial Hospital, Hefei

310003

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

310022

Zhejiang Cancer Hospital, Hangzhou

350014

Fujian Cancer Hospital, Fuzhou

450000

Henan Cancer Hospital, Zhengzhou

510655

The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT05119907 - Study of Sacituzumab Govitecan in Patients With Solid Tumor | Biotech Hunter | Biotech Hunter